646 related articles for article (PubMed ID: 12562577)
21. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.
Nordström AL; Nyberg S; Olsson H; Farde L
Arch Gen Psychiatry; 1998 Mar; 55(3):283-4. PubMed ID: 9510228
[No Abstract] [Full Text] [Related]
23. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
24. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
25. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
Markianos M; Hatzimanolis J; Lykouras L
Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
[TBL] [Abstract][Full Text] [Related]
27. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.
Kessler RM; Ansari MS; Riccardi P; Li R; Jayathilake K; Dawant B; Meltzer HY
Neuropsychopharmacology; 2005 Dec; 30(12):2283-9. PubMed ID: 16123775
[TBL] [Abstract][Full Text] [Related]
28. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
[TBL] [Abstract][Full Text] [Related]
29. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.
Raedler TJ; Knable MB; Lafargue T; Urbina RA; Egan MF; Pickar D; Weinberger DR
Psychiatry Res; 1999 Apr; 90(2):81-90. PubMed ID: 10482380
[TBL] [Abstract][Full Text] [Related]
30. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
[TBL] [Abstract][Full Text] [Related]
31. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
32. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
[TBL] [Abstract][Full Text] [Related]
33. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
[TBL] [Abstract][Full Text] [Related]
34. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
[TBL] [Abstract][Full Text] [Related]
35. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Dellva MA; Tran P; Tollefson GD; Wentley AL; Beasley CM
Psychiatr Serv; 1997 Dec; 48(12):1571-7. PubMed ID: 9406266
[TBL] [Abstract][Full Text] [Related]
36. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Tollefson GD; Sanger TM; Lu Y; Thieme ME
Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
[TBL] [Abstract][Full Text] [Related]
37. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.
Barak Y; Shamir E; Zemishlani H; Mirecki I; Toren P; Weizman R
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1199-202. PubMed ID: 12452546
[TBL] [Abstract][Full Text] [Related]
39. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
40. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Gomez JC; Crawford AM
J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
